Participants in trials who are taking these medicines should have their diabetes regimens reviewed by their clinical team
So while theres no final answer yet, these studies give you a pretty clear idea of what doses to expect if retatrutide gets approved
Phase 3 data for Retatrutide is expected to clarify whether the 24.2% Phase 2 result is reproducible at scale, potentially making it the most effective single compound in this class
They have clear biological explanations, and understanding those explanations can help you decide whether to push through, adjust your approach, or stop entirely
A comprehensive review of the literature was conducted to examine the etiology of HFpEF, the role of endothelial dysfunction, and the effects of GLP-1R agonists on endothelial function and heart failure outcomes
: It seems there is always a focus to invest heavily in treatments but far less in prevention